Read more
4:33 PM · 15 March 2024

Geron surges almost 100% after FDA vote

-
-
Open account Download free app

Geron (GERN.US), US biotechnology company, is surging almost 100% today! Share price surge comes in response to US Food and Drug Administration (FDA) advisory panel approving company's anemia drug candidate, Imetelstat. FDA panel voted 12-2 in favor of the drug, saying that its benefits of Imetelstat outweigh risks for the targeted patient population. While final approval from FDA is expected by June 16, 2024, FDA often follows recommendations of advisory panels.

While FDA is not obliged to follow advisory panel recommendations, a strongly positive 12-2 vote results shows that there is a very high chance of regulatory approval in June.

Taking a look at Geron chart (GERN.US) at D1 interval, we can see that today's surge is indeed massive. Stock bounced off the $1.70 support zone and rallied to the highest level since mid-June 2023. Advance has been halted at the $3.40 resistance zone, marked with local highs from the first half of 2023. Nevertheless, even after today's surge the stock is trading over 50% below its all-time highs from September 2018.

Source: xStation5

3 April 2026, 11:31 AM

DAX down 12% from all-time high 🚩Watch this 2 stocks in April

2 April 2026, 6:32 PM

Daily summary: Hopes for peace and space stocks in the spotlight

2 April 2026, 5:58 PM

Globalstar: Are we headed for a battle of giants over orbit?

2 April 2026, 5:43 PM

Intuitive Machines: Flywheel of the space economy?

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits